Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
10.95
-0.90 (-7.59%)
At close: May 30, 2025, 4:00 PM
10.96
+0.01 (0.09%)
After-hours: May 30, 2025, 4:20 PM EDT
Oruka Therapeutics Employees
Oruka Therapeutics had 28 employees as of December 31, 2024.
Employees
28
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,869,730
Market Cap
410.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ORKA News
- 10 days ago - Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 10 days ago - Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody - GlobeNewsWire
- 16 days ago - Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference - GlobeNewsWire
- 3 months ago - Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 3 months ago - Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Oruka Therapeutics to Present at Multiple March Investor Conferences - GlobeNewsWire
- 5 months ago - Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody - GlobeNewsWire